What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.
Overview
Jason V. Coloma, Chief Executive Officer of Maze Therapeutics (NASDAQ:MAZE), reported the indirect sale of 27,858 shares of common stock over three open-market transactions on June 22 and June 23, 2026, according to the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average reported price ($26.04).
Details
* 1-year performance is calculated using June 23, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.